Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Zinc Chloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.65 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.65 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.65 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.65 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.65 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.65 |
| ▸ | THRB | P10828 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Chloride SCHEMBL29837408 | 0.99 | TDP1 (0.64) | TDP1THRBMAPK1MEN1KMT2A | |
| Bromide SCHEMBL25280 | 0.94 | TDP1 (0.70) | TDP1THRBMAPK1MEN1KMT2A | |
| SCHEMBL12671027 | 0.94 | TDP1 (0.69) | TDP1THRBMAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL25301058 | 0.82 | TDP1 (0.80) | TDP1THRBMAPK1MEN1KMT2A | |
| Hexamethyl Pararosaniline SCHEMBL9171 | 0.81 | TDP1 (1.00) | TDP1THRBMAPK1MEN1KMT2A | |
| Zinc Ion SCHEMBL29366028 | 0.80 | TDP1 (0.75) | TDP1THRBMAPK1MEN1KMT2A | |
| Hexamethyl Pararosaniline SCHEMBL94116 | 0.79 | TDP1 (0.96) | TDP1THRBMAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5452767 | 0.77 | TDP1 (0.61) | TDP1THRBMAPK1MEN1KMT2A | |
| SCHEMBL889789 | 0.76 | TDP1 (0.44) | TDP1THRBMAPK1MEN1KMT2A | |
| Brilliant Green SCHEMBL28216 | 0.76 | TDP1 (0.88) | TDP1THRBMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12571798-B2 | Cancer biomarkers and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025226652-A9 | NUCLEIC ACID SEQUENCES FOR REDUCING CHEMORESISTANCE AND TREATING DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025226652-A2 | NUCLEIC ACID SEQUENCES FOR REDUCING CHEMORESISTANCE AND TREATING DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12404322-B2 | Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease | AXON NEUROSCIENCE SE (CY) | 2025-09-02 | — | — | US | disclosed |
| EP-4602078-A2 | COMPOSITIONS AND METHODS OF USING CELL-PENETRATING ANTIBODIES | Yale University (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12332245-B2 | Cancer biomarkers and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-17 | — | — | US | disclosed |
| US-12194082-B2 | Compositions and methods for treatment of homocystinuria | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3998067-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA | UNIV COLORADO REGENTS (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024081736-A2 | COMPOSITIONS AND METHODS OF USING CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240091325-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-03-21 | — | — | US | disclosed |
| EP-3796002-B1 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11771745-B2 | Compositions and methods for treatment of homocystinuria | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3618817-B1 | THERAPEUTIC EFFECTS OF GUANABENZ TREATMENT IN VANISHING WHITE MATTER | STICHTING VUMC (NL) | 2023-07-12 | — | — | EP | disclosed |
| US-20230204591-A1 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-29 | — | — | US | disclosed |
| US-11382920-B2 | Therapeutic effects of Guanabenz treatment in vanishing white matter | STICHTING VUMC (NL) | 2022-07-12 | — | — | US | disclosed |
| EP-3998067-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA | The Regents of the University of Colorado, a body corporate (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220125896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-04-28 | — | — | US | disclosed |
| CN-114375420-A | Photosensitive resin composition and photosensitive element | 旭化成株式会社 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571798-B2 | Cancer biomarkers and methods of use thereof | MKI67, BRCA1, CD68 | CHRM2 3174/4885CHRM1 3962/4885CHRM3 3850/4885 |
| US-11382920-B2 | Therapeutic effects of Guanabenz treatment in vanishing white matter | WIZ, GNMT, CLN6 | CHRM2 1409/4885CHRM1 1225/4885CHRM3 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.